Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in patients without diabetes with acute myocardial infarction
NCT04564742Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in acute myocardial infarction (AMI) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Hierarchical composite outcome of death, hospitalization for heart failure, non-fatal MI, atrial fibrillation/flutter, new diagnosis of type 2 diabetes mellitus, NYHA Class, and body weight decrease at 29 months. Started Dec 2020; status: completed.
02
Drugs
dapagliflozin
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT04564742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04564742.